Impact of prostate cancer multifocality on its biology and treatment

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 799-804

  Algaba, Ferran ^a   Montironi, Rodolfo ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER STAGING; CLINICAL EVALUATION; CORE NEEDLE BIOPSY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; FOCAL THERAPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MULTIPLE CANCER; NEEDLE BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECTUM BIOPSY; REVIEW; RISK FACTOR; THREE DIMENSIONAL IMAGING; TOPOGRAPHY; TREATMENT INDICATION; TUMOR VOLUME;

BIOPSY, NEEDLE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 77952555104     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0462     Document Type: Review

References (48)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
2. Polascik TJ, Mayes JM, Sun L, et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. Prostate 2008;68: 1380-1386.
3. Jones JS. Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 2007;8:165-172.
4. de la Rosette JJ, Mouraviev V, Polascik J. Focal targeted therapy will be a future treatment modality for early stage prostate cancer. Eur Urol 2009;8(suppl):424-432.
5. Iczkowski KA, Hossain D, Torkko KC, et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008;71:1166-1171.
6. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
7. Wehbi E, Musquera M, Alcaraz A, et al. Focal therapy will be the future treatment modality: The motion ''con''. Eur Urol 2009;8(suppl):433-438.
8. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: Does each focus matter? J Clin Oncol 2005;23:7497-7502.
9. Huguier M, Ferro L, Barrier A. Early gastric carcinoma: Spread and multicentricity. Gastric Cancer 2002;5:125-129.
10. Trousse D, D'Journo XB, Avaro JP, et al. Multifocal T4 nonsmall cell lung cancer: A subset with improved prognosis. Eur J Cardiothorac Surg 2008;33:99-103.
11. Dietlein M, Luyken WA, Schicha H, Larena-Avellaneda A. Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough? Nucl Med Commun 2005;26:3-8.
12. Blute ML, Itano NB, Cheville JC, et al. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 2003;169:1276-1281.
13. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005;66(suppl 1):4-34.
14. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-2366.
15. Miller GJ, Cygan JM. Morphology of prostate cancer: The effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994;152:1709-1713.
16. Stamatiou KN, Dilernia GC, Ilias GK, et al. The phenomenon of multifocality does not affect the biologic behavior of histologic prostate carcinoma. Med Sci Monit 2009;15: BR61-63.
17. Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol 2009;19:182-187.
18. Mouraviev V, Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110: 906-910.
19. Bastacky SI, Wojno KJ, Walsh PC, et al. Pathological features of hereditary prostate cancer. J Urol 1995;153:987-992.
20. Byar DP, Mostofi FK. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 1972;30:5-13.
21. Yoon GS, Wang W, Osunkoya AO, et al. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008;179:2203-2206.
22. Cheng L, Jones TD, Pan CX, et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005;18:1022-1026.
23. Bostwick DG, Graham SD Jr, Napalkov P, et al. Staging of early prostate cancer: A proposed tumor volume-based prognostic index. Urology 1993;41:403-411.
24. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
25. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
26. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
27. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008;30:190-198.
28. Egevad L. Recent trends in Gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol 2008;30:254-260.
29. Montironi R, Mazzuccheli R, Scarpelli M, et al. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: Contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005;95:1146-1152.
30. Billis A, Guimaraes MS, Freitas LL, et al. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008;180:548-553.
31. Helpap B, Egevad L. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. Anal Quant Cytol Histol 2008;30:133-138.
32. Helpap B, Egevad L. Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal Quant Cytol Histol 2008;30:1-7.
33. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 2003;170:459-463.
34. Ruijter ET, van de Kaa CA, Schalken JA, et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996;180: 295-299.
35. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
36. Presti JC. Prostate biopsy: Current status and limitations. Rev Urol 2007;9:93-98.
37. Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009;6:205-215.
38. Falzarone SM, Zhou M, Kodjoe E, et al. Can saturation biopsy predict significant cancer nodule localization in radical prostatectomy specimens: A correlative study and implications for focal therapy for prostate cancer. Mod Pathol 2009; 22(suppl 1):168A. Abstract 758.
39. Sartor AO, Hricak H, Wheeler TM, et al, Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008;72(suppl 6):S12-S24.
40. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009;27:4321-4326.
41. Egawa S, Takashima R, Matsumoto K, et al. Infrequent involvement of the anterior base in low-risk patients with clinically localized prostate cancer and its possible significance in definitive radiation therapy. Jpn J Clin Oncol 2000; 30:126-130.
42. Tiguert R, Gheiler EL, Tefilli MV, et al. Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. Prostate 1998;37:230-235.
43. Mazal PR, Haitel A, Windischberger C, et al. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001;39:662-668.
44. Chen ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci: Biopsy strategy implications. Cancer 2000;89:1800-1809.
45. Magi-Galluzi C, Jones S, Hernandez AV, Zhou M. Cancer to prostatic urethra distance in radical prostatectomy: Implications for urethral thermoprotection in prostate cryoablation surgery. Mod Pathol 2009;22(suppl 1):181A. Abstract 818.
46. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007;70:630-633.
47. Merrimen JL, Jones G, Walker D, et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 2009;182:485-490.
48. Pierorazio PM, Lambert SM, Matsukhani M, et al. Highgrade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU Int 2007;100:1066-7100.